Literature DB >> 33615483

Increased PD-L1 Expression in Human Skin Acutely and Chronically Exposed to UV Irradiation.

Sally E Dickinson1,2, Maria Khawam2, Viktoria Kirschnerova2, Prajakta Vaishampayan2, Sara M Centuori2,3, Kathylynn Saboda2, Valerie S Calvert4, Emanuel F Petricoin4, Clara Curiel-Lewandrowski2,5.   

Abstract

Overexpression of PD-L1 (CD274) on tumor cells may represent a hallmark of immune evasion, and overexpression has been documented in several tumors including cutaneous squamous cell carcinoma (cSCC). While PD-L1/PD-1 activity in the skin has been primarily described in inflammatory models, our goal was to examine PD-L1 expression in human keratinocytes exposed to UV irradiation. We assessed PD-L1 expression in human sun-protected (SP) and sun-damaged (SD) skin, actinic keratosis (AK), and cSCC using IHC and protein microarray. Both methods found low baseline levels of PD-L1 in SP and SD skin and significantly increased expression in cSCC. Next, we examined PD-L1 expression in acute models of UV exposure. In human SP skin exposed to 2-3 MED of UV (n = 20), epidermal PD-L1 was induced in 70% of subjects after 24 h (P = 0.0001). SKH-1 mice exposed to acute UV also showed significant epidermal PD-L1 induction at 16, 24 and 48 h. A time- and dose-dependent induction of PD-L1 was confirmed in cultured human keratinocytes after UV, which was markedly reduced in the presence of MEK/ERK, JNK or STAT3 inhibitors. These findings suggest that UV induces upregulation of PD-L1 through established, pharmacologically targetable stress-signaling pathways in keratinocytes.
© 2021 American Society for Photobiology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33615483      PMCID: PMC8277687          DOI: 10.1111/php.13406

Source DB:  PubMed          Journal:  Photochem Photobiol        ISSN: 0031-8655            Impact factor:   3.521


  28 in total

1.  Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.

Authors:  Michael R Green; Scott Rodig; Przemyslaw Juszczynski; Jing Ouyang; Papiya Sinha; Evan O'Donnell; Donna Neuberg; Margaret A Shipp
Journal:  Clin Cancer Res       Date:  2012-01-23       Impact factor: 12.531

Review 2.  Mutations in cancer genes of UV-induced skin tumors of hairless mice.

Authors:  H J van Kranen; F R de Gruijl
Journal:  J Epidemiol       Date:  1999-12       Impact factor: 3.211

Review 3.  Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma.

Authors:  Patcharee Ritprajak; Miyuki Azuma
Journal:  Oral Oncol       Date:  2014-12-12       Impact factor: 5.337

4.  Activation of the PI3K/Akt/mTOR and MAPK Signaling Pathways in Response to Acute Solar-Simulated Light Exposure of Human Skin.

Authors:  Yira Bermudez; Steven P Stratton; Clara Curiel-Lewandrowski; James Warneke; Chengcheng Hu; George T Bowden; Sally E Dickinson; Zigang Dong; Ann M Bode; Kathylynn Saboda; Christine A Brooks; Emanuel F Petricoin; Craig A Hurst; David S Alberts; Janine G Einspahr
Journal:  Cancer Prev Res (Phila)       Date:  2015-06-01

Review 5.  Immunoregulatory molecule B7-H1 (CD274) contributes to skin carcinogenesis.

Authors:  Yujia Cao; Lu Zhang; Pacharee Ritprajak; Fumihiko Tsushima; Pornpan Youngnak-Piboonratanakit; Yosuke Kamimura; Masaaki Hashiguchi; Miyuki Azuma
Journal:  Cancer Res       Date:  2011-07-05       Impact factor: 12.701

Review 6.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

7.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.

Authors:  Y Agata; A Kawasaki; H Nishimura; Y Ishida; T Tsubata; H Yagita; T Honjo
Journal:  Int Immunol       Date:  1996-05       Impact factor: 4.823

8.  Inhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin.

Authors:  Sally E Dickinson; Jaroslav Janda; Jane Criswell; Karen Blohm-Mangone; Erik R Olson; Zhonglin Liu; Christy Barber; Emanuel F Petricoin; Valerie S Calvert; Janine Einspahr; Jesse E Dickinson; Steven P Stratton; Clara Curiel-Lewandrowski; Kathylynn Saboda; Chengcheng Hu; Ann M Bode; Zigang Dong; David S Alberts; G Timothy Bowden
Journal:  Cancer Prev Res (Phila)       Date:  2016-01-22

9.  PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.

Authors:  Michael R Migden; Danny Rischin; Chrysalyne D Schmults; Alexander Guminski; Axel Hauschild; Karl D Lewis; Christine H Chung; Leonel Hernandez-Aya; Annette M Lim; Anne Lynn S Chang; Guilherme Rabinowits; Alesha A Thai; Lara A Dunn; Brett G M Hughes; Nikhil I Khushalani; Badri Modi; Dirk Schadendorf; Bo Gao; Frank Seebach; Siyu Li; Jingjin Li; Melissa Mathias; Jocelyn Booth; Kosalai Mohan; Elizabeth Stankevich; Hani M Babiker; Irene Brana; Marta Gil-Martin; Jade Homsi; Melissa L Johnson; Victor Moreno; Jiaxin Niu; Taofeek K Owonikoko; Kyriakos P Papadopoulos; George D Yancopoulos; Israel Lowy; Matthew G Fury
Journal:  N Engl J Med       Date:  2018-06-04       Impact factor: 91.245

Review 10.  PD-L1 expression in human cancers and its association with clinical outcomes.

Authors:  Xin Wang; Feifei Teng; Li Kong; Jinming Yu
Journal:  Onco Targets Ther       Date:  2016-08-12       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.